Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AlvotechNASDAQ: ALVO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 56.5%

Gross margin was 56.5% in Q1 FY2026, up 5.8 pp from a year earlier. On a trailing-twelve-month basis it was 61.4%, up 0.8 pp year over year. Over 3 fiscal years it widened by 37.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.5%-6.7 pp QoQ
Last fiscal yearDec 2025
59.8%-2.3 pp YoY
LTMMar 2026
61.4%+0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.8 pp——
1 year-2.3 pp——
3 years+37.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
59.8%
Year-over-year change
-2.3pp

Gross Margin vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 gross margin of 61.4% is the 5th highest of the 11 companies compared; the peer median is 57.7%.
  • Its year-over-year change of +0.8 pp is the 5th highest of 11, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +37.0 pp compares with a peer median of -0.5 pp.
ALVO Competitors Peer median
Gross Margin for ALVO and competitors
Company Period LTM level YoY 3-year change
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202684.9% -0.7 pp-0.6 pp
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BIIBBiogen Inc.LTM Jun 202667.7% -4.8 pp-7.1 pp
ALVOAlvotechLTM Mar 202661.4% +0.8 pp+37.0 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 202654.8% -3.7 pp-13.9 pp
OGNOrganon & Co.LTM Sep 202653.4% -1.6 pp-8.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
Peer median (excluding ALVO) 57.7%-0.6 pp-0.5 pp

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.77M83.03M91.43M489.68M586.32M
Cost of Revenue064.1M160.86M185.31M235.56M
Gross Profit36.77M18.93M(69.42M)304.37M350.76M
Gross Margin100.0%22.8%-75.9%62.2%59.8%
Research & Development191.01M180.62M210.83M171.31M184.19M
Selling, General & Admin84.13M186.74M73.04M61.45M90.95M
Operating Expenses272.23M365.38M285.44M234.73M272.56M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
EBITDA(18.03M)(439.8M)(493.67M)(32.28M)323.39M
EBITDA Margin-49.0%-529.7%-539.9%-6.6%55.2%
Operating Income(235.46M)(346.44M)(354.86M)69.64M78.21M
Operating Margin-640.3%-417.3%-388.1%14.2%13.3%
Interest Income19K912K4.82M4.62M198.49M
Interest Expense112.97M91.44M134.82M157.6M149.19M
Other Income / Expenses86.26M(205.21M)(296.19M)(287.21M)58.14M
Income Before Tax(149.2M)(551.65M)(651.05M)(217.56M)136.35M
Pre-Tax Margin-405.7%-664.4%-712.0%-44.4%23.3%
Income Tax Expense(47.69M)(38.07M)(99.32M)14.3M108.43M
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Net Margin-276.0%-618.6%-603.4%-47.3%4.8%
EPS (Basic)(3.25)(2.60)(2.43)(0.87)0.10
EPS (Diluted)(3.25)(2.60)(2.43)(0.87)0.10
Weighted Avg Shares31.25M197.72M227.26M267.92M279.19M
Weighted Avg Shares (Diluted)31.25M197.72M227.26M267.92M279.19M

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.